Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

is of safety and efficacy to be conducted based on predefined criteria. Kosan anticipates providing more information on the TIME-1 trial design upon initiation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is designed to enroll approximately 130 patients with relapsed-refractory multiple myeloma. The trial is designed to test three different doses of tanespimycin in combination with the approved dose and schedule of bortezomib (Velcade(R)) (1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and 340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour intravenous infusion on a cycle of two weeks of treatment every three weeks (the same schedule as bortezomib). Patients eligible to participate in the TIME-2 trial must have been treated with and progressed following at least three prior treatments for multiple myeloma. Prior regimens must include bortezomib and lenalidomide (Revlimid(R)). The primary endpoint of the trial is the dose response based on objective response rate after 4 cycles of treatment. Secondary endpoints include a comparison of response rate between the three dose groups, progression-free survival, time to treatment failure and overall survival. Objective response rate in multiple myeloma is measured primarily by the patient's level of M protein.

About the Special Protocol Assessment

As stated in the Prescription Drug User Fee Act (PDUFA) and FDA's Guidance for Industry Special Protocol Assessment, "...having agreed to the design, execution, and analyses proposed in protocols reviewed under this process ... the Agency will not later alter its perspective on the issues of design, execution, or analyses unless public health concerns unrecognized at the time of protocol assessment under this process are evident. Thus, documented special protocol assessments should be considered binding on the review division and should not be changed at any time..." as
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 04, 2015 Research ... addition of the "MRI Systems Market to ... Efficiency, with Growth Driven by Developing Economies" ... Market to 2020 - Focus on Patient Comfort ... Economies" discusses the market, competitive landscape, and trends ...
(Date:8/4/2015)... and LOS ANGELES , Aug. ... DGX ), the world,s leading provider of diagnostic ... the previously announced acquisition of MemorialCare Health System,s ... a result of the transaction, patients and physicians ... innovative services and network of nearly 200 patient ...
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... Sosei Group Corporation,("Sosei"; TSE Mothers Index: 4565), ... Japanese Phase III clinical trial for the,emergency contraceptive ... rights to the product in Japan from HRA ... evaluate the safety and prevented,pregnancy rate of SOH-075 ...
... Americans, WASHINGTON, July 9 In a congressional,hearing ... the,safety and importance of the research programs operated by ... absolute commitment to its patients,while expressing regret that even ... "VA has an outstanding research program, and has been ...
Cached Medicine Technology:Sosei Announces Completion of Phase III Trial for NorLevo(R) 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3
(Date:8/4/2015)... ... August 04, 2015 , ... How cool is it to check in at ... The new "Now" feature will soon allow you to do just that. , Ahhaa ... other using the now feature. , Users will soon get to share what inspires ...
(Date:8/4/2015)... ... 2015 , ... World Patent Marketing, a vertically integrated manufacturer ... invention that eliminates the need to have a partner or trainer when using ... worth $30 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:8/4/2015)... WASHINGTON, D.C. (PRWEB) , ... August 04, 2015 ... ... issues fellowship focused on sexual and reproductive health and rights in Indonesia for ... Journalists will visit a number of sites in Indonesia and attend the International ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... An ... that found financial incentives to be a viable method for encouraging people to lose ... money on the future of their weight loss success, adding a financial incentive to ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... ... are suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, ... the only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands ...
Breaking Medicine News(10 mins):Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3
... Practice DirectorWESTFIELD, Ind., Feb. 10 maxIT Healthcare ... new division to provide technical and functional professional ... Healthcare, a leading professional services company for healthcare ... a presence in the health insurance market to ...
... de foie gras is discussed by Michael Greger of The ... forthcoming issue of the International Journal of Food Safety, ... as amyloid fibrils associated with damage to brain cells in ... can be present in the meat of poultry and mammals. ...
... launch a new national research centre to further understanding ... Centre, which will be opened by Sir William Stewart, ... 12 in the country to be funded by the ... the Government,s health research strategy. The joint venture has ...
... CHARLOTTE, N.C., Feb. 10 USHIFU, a worldwide ... invasive high intensity focused,ultrasound technologies, is pleased to ... consulting position of Chief Medical Officer. Dr.,Schoenberg is ... Urologic,Oncology who has authored more than 100 peer-reviewed ...
... 10 Erdman, A Cogdell Spencer,Company is pleased ... has earned the U.S. Environmental Protection Agency,s (EPA,s),prestigious ... efficiency,and environmental protection. America,s commercial buildings and industrial,plants ... similar facilities for energy,efficiency may qualify for the ...
... NUVA ), a medical device company focused ... the spine, announced today that Kevin O,Boyle, Executive Vice ... at the ROTH 21st Annual OC Growth Stock Conference ... Tuesday, February 17, 2009, at 11:30 a.m. PT.A live ...
Cached Medicine News:Health News:maxIT Healthcare Launches Healthcare Payer Professional Services Unit 2Health News:Give the foie gras a miss 2Health News:Biomedical research center opens in Liverpool 2Health News:USHIFU Appoints Mark Schoenberg, M.D. Chief Medical Officer 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 3Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 4Health News:NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference 2Health News:NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference 3
A simple solution to hand assisted laparoscopic surgery....
... The HandPort Systems non-adhesive ... during Hand-Assisted Laparoscopic Surgrery (HALS) ... touch, grasp, and palpate throughout. ... small as 6 cm, patients ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
Medicine Products: